22 , 23 Our discoveries illustrated that CCL2 affects the activation of MAPKs in M‐MDSCs and that CCL2 stimulated M‐MDSC‐modulated impedance of T lymphocytes raising the question of whether M‐MDSCs, CCL2, and M‐MDSC/CCL2‐regulated suppression of T lymphocytes in tumor microenvironment might be significant factors to consider when identifying the reason why current ICP therapies might not take effect on all tumor‐bearing patients.
← all excerpts
CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid-derived suppressor cells.
1
—
—